Oppenheimer & Co. Inc. lifted its holdings in shares of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) by 33.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 120,000 shares of the biotechnology company’s stock after purchasing an additional 30,000 shares during the quarter. Oppenheimer & Co. Inc. owned about 0.53% of Catabasis Pharmaceuticals worth $169,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Renaissance Technologies LLC purchased a new position in shares of Catabasis Pharmaceuticals during the 1st quarter worth $106,000. Hedge funds and other institutional investors own 32.90% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/09/23/catabasis-pharmaceuticals-inc-catb-shares-bought-by-oppenheimer-co-inc.html.

Catabasis Pharmaceuticals, Inc. (NASDAQ CATB) opened at 1.82 on Friday. The company’s 50-day moving average price is $1.57 and its 200-day moving average price is $1.57. The stock’s market capitalization is $40.92 million. Catabasis Pharmaceuticals, Inc. has a one year low of $1.08 and a one year high of $7.89.

Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.08. Equities research analysts predict that Catabasis Pharmaceuticals, Inc. will post ($1.39) EPS for the current year.

A number of equities analysts have recently weighed in on CATB shares. Oppenheimer Holdings, Inc. lowered their price target on Catabasis Pharmaceuticals from $9.00 to $4.00 and set an “outperform” rating for the company in a report on Tuesday, August 15th. HC Wainwright raised their target price on Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the company a “buy” rating in a report on Monday, August 14th. Finally, Wedbush restated an “outperform” rating and set a $4.00 target price on shares of Catabasis Pharmaceuticals in a report on Wednesday, June 21st. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $4.50.

Catabasis Pharmaceuticals Profile

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Want to see what other hedge funds are holding CATB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB).

Institutional Ownership by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.